Plandai Biotechnology Inc (PLPL)

[Stockfun1]

$TXTM Company has come to an agreement with Plandai Biotechnology (PLPL) to cancel 100% of the Series D Preferred, which gave PLPL voting control over TXTM and 75% conversion rights.....1/2

— Protext Pharma, Inc ($TXTM) (@protxtm) May 5, 2020

2/2 $TXTM Additionally, the amount of shares payable to PLPL has been amended from 50m to 10m common shares. Protext continues to retain 100% ownership in its two acquisitions completed with PLPL including all licenses and rights under the agreements.

— Protext Pharma, Inc ($TXTM) (@protxtm) May 5, 2020